Iovance Biotherapeutics (IOVA) Shares Up 0%

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shot up 0% on Wednesday . The company traded as high as $9.90 and last traded at $9.60. 926,127 shares changed hands during mid-day trading, an increase of 74% from the average session volume of 532,666 shares. The stock had previously closed at $9.60.

A number of research firms recently weighed in on IOVA. B. Riley upped their price target on Iovance Biotherapeutics from $17.50 to $18.00 and gave the stock a “buy” rating in a report on Wednesday, November 1st. Zacks Investment Research cut Iovance Biotherapeutics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. HC Wainwright set a $16.00 price target on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Wednesday. Finally, Oppenheimer set a $13.00 price target on Iovance Biotherapeutics and gave the stock a “buy” rating in a report on Tuesday, October 31st. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Iovance Biotherapeutics has a consensus rating of “Buy” and a consensus target price of $14.72.

The company has a market capitalization of $699.09, a P/E ratio of -7.35 and a beta of 4.89.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). equities analysts predict that Iovance Biotherapeutics Inc will post -1.36 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of IOVA. Russell Investments Group Ltd. purchased a new stake in Iovance Biotherapeutics in the 2nd quarter valued at approximately $380,000. Schwab Charles Investment Management Inc. purchased a new stake in Iovance Biotherapeutics in the 2nd quarter valued at approximately $1,538,000. Rhumbline Advisers purchased a new stake in Iovance Biotherapeutics in the 2nd quarter valued at approximately $468,000. Bank of New York Mellon Corp purchased a new stake in Iovance Biotherapeutics in the 2nd quarter valued at approximately $1,796,000. Finally, Legal & General Group Plc purchased a new position in shares of Iovance Biotherapeutics during the 2nd quarter worth $103,000. 75.93% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3145933/iovance-biotherapeutics-iova-shares-up-0.html.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Receive News & Ratings for Iovance Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iovance Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.